THORNE HEALTHTECH INC (THRN) Fundamental Analysis & Valuation

NASDAQ:THRN • US8852601090

Current stock price

10.19 USD
-0.01 (-0.1%)
At close:
10.17 USD
-0.02 (-0.2%)
After Hours:

This THRN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

4

1. THRN Profitability Analysis

1.1 Basic Checks

  • In the past year THRN was profitable.
  • THRN had a positive operating cash flow in the past year.
THRN Yearly Net Income VS EBIT VS OCF VS FCFTHRN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 0 10M -10M -20M

1.2 Ratios

  • With a decent Return On Assets value of 7.20%, THRN is doing good in the industry, outperforming 75.00% of the companies in the same industry.
  • The Return On Equity of THRN (13.21%) is better than 75.00% of its industry peers.
  • THRN has a Return On Invested Capital of 4.69%. This is comparable to the rest of the industry: THRN outperforms 55.00% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for THRN is significantly below the industry average of 11.42%.
  • The last Return On Invested Capital (4.69%) for THRN is above the 3 year average (2.99%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 7.2%
ROE 13.21%
ROIC 4.69%
ROA(3y)2.02%
ROA(5y)N/A
ROE(3y)2.55%
ROE(5y)N/A
ROIC(3y)2.99%
ROIC(5y)N/A
THRN Yearly ROA, ROE, ROICTHRN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 0 -20 -40 -60

1.3 Margins

  • THRN's Profit Margin of 7.94% is fine compared to the rest of the industry. THRN outperforms 70.00% of its industry peers.
  • The Operating Margin of THRN (5.26%) is comparable to the rest of the industry.
  • The Gross Margin of THRN (50.15%) is comparable to the rest of the industry.
  • THRN's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 5.26%
PM (TTM) 7.94%
GM 50.15%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.81%
GM growth 5YN/A
THRN Yearly Profit, Operating, Gross MarginsTHRN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 0 20 -20 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. THRN Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so THRN is destroying value.
  • Compared to 1 year ago, THRN has more shares outstanding
  • THRN has a worse debt/assets ratio than last year.
THRN Yearly Shares OutstandingTHRN Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 10M 20M 30M 40M 50M
THRN Yearly Total Debt VS Total AssetsTHRN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 50M 100M 150M 200M

2.2 Solvency

  • An Altman-Z score of 3.41 indicates that THRN is not in any danger for bankruptcy at the moment.
  • THRN has a Altman-Z score of 3.41. This is in the better half of the industry: THRN outperforms 67.50% of its industry peers.
  • A Debt/Equity ratio of 0.17 indicates that THRN is not too dependend on debt financing.
  • THRN has a Debt to Equity ratio (0.17) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.17
Debt/FCF N/A
Altman-Z 3.41
ROIC/WACC0.5
WACC9.44%
THRN Yearly LT Debt VS Equity VS FCFTHRN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 0 50M 100M

2.3 Liquidity

  • THRN has a Current Ratio of 2.41. This indicates that THRN is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of THRN (2.41) is better than 70.00% of its industry peers.
  • A Quick Ratio of 1.13 indicates that THRN should not have too much problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 1.13, THRN is in line with its industry, outperforming 50.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.41
Quick Ratio 1.13
THRN Yearly Current Assets VS Current LiabilitesTHRN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. THRN Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 660.00% over the past year.
  • The Revenue has grown by 23.25% in the past year. This is a very strong growth!
  • THRN shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 30.66% yearly.
EPS 1Y (TTM)660%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%172.73%
Revenue 1Y (TTM)23.25%
Revenue growth 3Y30.66%
Revenue growth 5YN/A
Sales Q2Q%29.69%

3.2 Future

  • Based on estimates for the next years, THRN will show a very strong growth in Earnings Per Share. The EPS will grow by 55.06% on average per year.
  • THRN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 21.84% yearly.
EPS Next Y14.31%
EPS Next 2Y46.48%
EPS Next 3Y55.06%
EPS Next 5YN/A
Revenue Next Year23.62%
Revenue Next 2Y24.38%
Revenue Next 3Y21.84%
Revenue Next 5YN/A

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
THRN Yearly Revenue VS EstimatesTHRN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M
THRN Yearly EPS VS EstimatesTHRN Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 0.2 0.4 0.6 0.8 1

More info and screens

Find the best growth stocksShow best growing peers

3

4. THRN Valuation Analysis

4.1 Price/Earnings Ratio

  • THRN is valuated quite expensively with a Price/Earnings ratio of 26.82.
  • Based on the Price/Earnings ratio, THRN is valued a bit cheaper than the industry average as 65.00% of the companies are valued more expensively.
  • The average S&P500 Price/Earnings ratio is at 25.51. THRN is around the same levels.
  • A Price/Forward Earnings ratio of 16.38 indicates a correct valuation of THRN.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of THRN indicates a somewhat cheap valuation: THRN is cheaper than 77.50% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 22.76, THRN is valued a bit cheaper.
Industry RankSector Rank
PE 26.82
Fwd PE 16.38
THRN Price Earnings VS Forward Price EarningsTHRN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • THRN's Enterprise Value to EBITDA ratio is in line with the industry average.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 28.54
THRN Per share dataTHRN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates THRN does not grow enough to justify the current Price/Earnings ratio.
  • A more expensive valuation may be justified as THRN's earnings are expected to grow with 55.06% in the coming years.
PEG (NY)1.87
PEG (5Y)N/A
EPS Next 2Y46.48%
EPS Next 3Y55.06%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. THRN Dividend Analysis

5.1 Amount

  • No dividends for THRN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

THRN Fundamentals: All Metrics, Ratios and Statistics

THORNE HEALTHTECH INC

NASDAQ:THRN (10/13/2023, 8:22:18 PM)

After market: 10.17 -0.02 (-0.2%)

10.19

-0.01 (-0.1%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupHousehold & Personal Products
GICS IndustryPersonal Care Products
Earnings (Last)08-08
Earnings (Next)11-09
Inst Owners0.03%
Inst Owner Change0%
Ins Owners10.68%
Ins Owner Change0%
Market Cap550.67M
Revenue(TTM)255.95M
Net Income(TTM)20.33M
Analysts80
Price Target8.61 (-15.51%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-40.77%
Min EPS beat(2)-112.25%
Max EPS beat(2)30.72%
EPS beat(4)2
Avg EPS beat(4)-25.45%
Min EPS beat(4)-112.25%
Max EPS beat(4)30.72%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.37%
Min Revenue beat(2)-3.4%
Max Revenue beat(2)4.13%
Revenue beat(4)1
Avg Revenue beat(4)-4.4%
Min Revenue beat(4)-9.72%
Max Revenue beat(4)4.13%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.28%
PT rev (3m)20.57%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)5.69%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.7%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.81%
Valuation
Industry RankSector Rank
PE 26.82
Fwd PE 16.38
P/S 2.15
P/FCF N/A
P/OCF 25.59
P/B 3.58
P/tB 4.63
EV/EBITDA 28.54
EPS(TTM)0.38
EY3.73%
EPS(NY)0.62
Fwd EY6.11%
FCF(TTM)-0.28
FCFYN/A
OCF(TTM)0.4
OCFY3.91%
SpS4.74
BVpS2.85
TBVpS2.2
PEG (NY)1.87
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 7.2%
ROE 13.21%
ROCE 5.95%
ROIC 4.69%
ROICexc 5.07%
ROICexgc 6.08%
OM 5.26%
PM (TTM) 7.94%
GM 50.15%
FCFM N/A
ROA(3y)2.02%
ROA(5y)N/A
ROE(3y)2.55%
ROE(5y)N/A
ROIC(3y)2.99%
ROIC(5y)N/A
ROICexc(3y)4.22%
ROICexc(5y)N/A
ROICexgc(3y)5.36%
ROICexgc(5y)N/A
ROCE(3y)3.82%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.81%
GM growth 5YN/A
F-Score5
Asset Turnover0.91
Health
Industry RankSector Rank
Debt/Equity 0.17
Debt/FCF N/A
Debt/EBITDA 1.31
Cap/Depr 590.87%
Cap/Sales 14.33%
Interest Coverage 19.78
Cash Conversion 109.39%
Profit Quality N/A
Current Ratio 2.41
Quick Ratio 1.13
Altman-Z 3.41
F-Score5
WACC9.44%
ROIC/WACC0.5
Cap/Depr(3y)158.15%
Cap/Depr(5y)N/A
Cap/Sales(3y)4.08%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)660%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%172.73%
EPS Next Y14.31%
EPS Next 2Y46.48%
EPS Next 3Y55.06%
EPS Next 5YN/A
Revenue 1Y (TTM)23.25%
Revenue growth 3Y30.66%
Revenue growth 5YN/A
Sales Q2Q%29.69%
Revenue Next Year23.62%
Revenue Next 2Y24.38%
Revenue Next 3Y21.84%
Revenue Next 5YN/A
EBIT growth 1Y1143.38%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year248.89%
EBIT Next 3Y103.9%
EBIT Next 5YN/A
FCF growth 1Y-266.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y78.29%
OCF growth 3YN/A
OCF growth 5YN/A

THORNE HEALTHTECH INC / THRN Fundamental Analysis FAQ

What is the ChartMill fundamental rating of THORNE HEALTHTECH INC (THRN) stock?

ChartMill assigns a fundamental rating of 4 / 10 to THRN.


What is the valuation status for THRN stock?

ChartMill assigns a valuation rating of 3 / 10 to THORNE HEALTHTECH INC (THRN). This can be considered as Overvalued.


What is the profitability of THRN stock?

THORNE HEALTHTECH INC (THRN) has a profitability rating of 4 / 10.


Can you provide the financial health for THRN stock?

The financial health rating of THORNE HEALTHTECH INC (THRN) is 4 / 10.


What is the earnings growth outlook for THORNE HEALTHTECH INC?

The Earnings per Share (EPS) of THORNE HEALTHTECH INC (THRN) is expected to grow by 14.31% in the next year.